Viewing Study NCT05878028


Ignite Creation Date: 2025-12-26 @ 11:14 AM
Ignite Modification Date: 2026-02-03 @ 5:27 AM
Study NCT ID: NCT05878028
Status: RECRUITING
Last Update Posted: 2024-05-23
First Post: 2023-05-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC
Sponsor: Quanli Gao
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None L-TIL View
None PD1 antibody resistance View
None Tislizumab View
None Chemotherapy View